tokens: Alirocumab reduced lipoprotein(a ) by a median 23.2 % with greater absolute reductions from higher baseline levels and no overall effect on incident type 2 diabetes ( hazard ratio 0.95 , 95 % CI 0.85 - 1.05 ) .